Literature DB >> 28379055

Performance of apparent diffusion coefficient of medial and lateral rectus muscles in Graves' orbitopathy.

Ahmed Ak Abdel Razek1, Mohamed El-Hadidy2, Mohamed E Moawad2, Nader El-Metwaly3, Amr A El-Said2.   

Abstract

Objective The purpose of this study was to determine the performance of the apparent diffusion coefficient in the detection of involvement of the medial and lateral rectus muscles in patients with Graves' orbitopathy. Methods and materials This prospective study was conducted on 33 consecutive patients (16 males, 17 females with a mean age of 36 years) with Graves' orbitopathy and 18 age- and sex-matched volunteers. The patients and volunteers underwent diffusion-weighted magnetic resonance imaging of the orbit in the axial plane using echo-planar imaging. The apparent diffusion coefficient of the medial and lateral rectus muscles was calculated. Results The medial rectus muscle was more affected than the lateral rectus muscle. The mean apparent diffusion coefficient value of the medial and lateral rectus muscles was 1.81 ± 0.19 and 1.72 ± 0.07 × 10-3 mm2/s in patients with Graves' orbitopathy and 1.59 ± 0.06 and 1.51 ± 0.06 × 10-3 mm2/s in volunteers, respectively. There was a significant difference in apparent diffusion coefficient values of the medial and lateral rectus muscles between patients with Graves' orbitopathy and volunteers ( p = 0.001). The classification performance as measured with area under the receiver operator characteristic curve was 0.89 (95% confidence interval: 0.732-0.904). The best performing threshold of the apparent diffusion coefficient value of the medial rectus muscle was 1.69 × 10-3 mm2/s and associated efficiency was 86%, sensitivity was 97%, and specificity was 97%. Conclusion We concluded that the apparent diffusion coefficient of the medial rectus muscle can be used for diagnosis of Graves' orbitopathy.

Entities:  

Keywords:  Diffusion; Graves; magnetic resonance imaging; orbit

Mesh:

Year:  2017        PMID: 28379055      PMCID: PMC5480799          DOI: 10.1177/1971400917691993

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  36 in total

1.  Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy.

Authors:  Seigo Tachibana; Tsukasa Murakami; Hitoshi Noguchi; Yasushi Noguchi; Akiko Nakashima; Yufuko Ohyabu; Shiro Noguchi
Journal:  Endocr J       Date:  2010-08-19       Impact factor: 2.349

2.  Differentiation between benign and malignant orbital tumors at 3-T diffusion MR-imaging.

Authors:  Ahmed Abdel Khalek Abdel Razek; Sahar Elkhamary; Amani Mousa
Journal:  Neuroradiology       Date:  2011-02-01       Impact factor: 2.804

3.  Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg.

Authors:  Letterio Salvatore Politi; Claudia Godi; Gabriella Cammarata; Alessandro Ambrosi; Antonella Iadanza; Roberto Lanzi; Andrea Falini; Stefania Bianchi Marzoli
Journal:  Eur Radiol       Date:  2014-02-12       Impact factor: 5.315

Review 4.  The pathophysiology of thyroid eye disease.

Authors:  Shannon J C Shan; Raymond S Douglas
Journal:  J Neuroophthalmol       Date:  2014-06       Impact factor: 3.042

5.  Graves' ophthalmopathy: the role of diffusion-weighted imaging in detecting involvement of extraocular muscles in early period of disease.

Authors:  R Kilicarslan; A Alkan; M M Ilhan; H Yetis; A Aralasmak; E Tasan
Journal:  Br J Radiol       Date:  2014-12-19       Impact factor: 3.039

Review 6.  MRI of retinoblastoma.

Authors:  A A K A Razek; S Elkhamary
Journal:  Br J Radiol       Date:  2011-09       Impact factor: 3.039

7.  Graves' orbitopathy: extraocular muscle/total orbit area ratio is positively related to the Clinical Activity Score.

Authors:  Rosario Le Moli; Alessandro Pluchino; Vincenzo Muscia; Concetto Regalbuto; Bruno Luciani; Sebastiano Squatrito; Riccardo Vigneri
Journal:  Eur J Ophthalmol       Date:  2012 May-Jun       Impact factor: 2.597

8.  Dynamic susceptibility contrast perfusion MR imaging in distinguishing malignant from benign head and neck tumors: a pilot study.

Authors:  Ahmed Abdel Khalek Abdel Razek; Lamiaa Galal Elsorogy; Nermin Yehia Soliman; Nadia Nada
Journal:  Eur J Radiol       Date:  2009-08-19       Impact factor: 3.528

Review 9.  Diagnostic criteria for Graves' ophthalmopathy.

Authors:  G B Bartley; C A Gorman
Journal:  Am J Ophthalmol       Date:  1995-06       Impact factor: 5.258

10.  Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study.

Authors:  E Kampmann; T Diana; M Kanitz; D Hoppe; G J Kahaly
Journal:  Int J Endocrinol       Date:  2015-06-28       Impact factor: 3.257

View more
  4 in total

1.  Retinal nerve fiber layer thickness measured by optical coherence tomography predicts visual recovery after orbital decompression for dysthyroid optic neuropathy.

Authors:  Xinghua Wang; Fagang Jiang; Shengnan Cheng; Yueqi Yu; Yayan You; Jin Chen; Xiaohuan Pi
Journal:  Int Ophthalmol       Date:  2021-05-04       Impact factor: 2.031

2.  Non-EPI-DWI for Detection, Disease Monitoring, and Clinical Decision-Making in Thyroid Eye Disease.

Authors:  C Feeney; R K Lingam; V Lee; F Rahman; S Nagendran
Journal:  AJNR Am J Neuroradiol       Date:  2020-08       Impact factor: 3.825

3.  Assessment of lacrimal glands in thyroid eye disease with diffusion-weighted magnetic resonance imaging.

Authors:  Ahmed Abdel Razek; El-Hadidy Mohamed El-Hadidy; Mohamed El-Said Moawad; Nader El-Metwaly; Amr Abd El-Hamid El-Said
Journal:  Pol J Radiol       Date:  2019-03-08

4.  Diffusion Tensor Imaging Technology to Quantitatively Assess Abnormal Changes in Patients With Thyroid-Associated Ophthalmopathy.

Authors:  Li Rui; Li Jing; Wang Zhenchang
Journal:  Front Hum Neurosci       Date:  2022-02-04       Impact factor: 3.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.